|
|
|
| |
Basic InformationMore InformationTestsLatest NewsQuestions and AnswersBlog EntriesDepression, ADHD, Psychotherapy and MedicationAdult AD/HD: Effects on Relationships and Self-EsteemThe Brain, Nutrition and ADHD"I Can't," Living with ADHDExploring the Upside of ADHDDo I Have ADD?Mindfulness and ADHD: A Tip from Dr. Lidia ZylowskaADHD - Breaking the Cycle of ShameADHD, Medication and ExercisePersonality Disorders and Attention Deficit/Hyperactivity DisorderAdolescents with ADHD and the Risk of Internet AddictionMindful Approaches for Adult ADHDChildren, ADHD and Stimulant MedicationThere is No Such Thing as ADDADHD and Brain Stimulation ADHD and Stimulant Medications, A Matter of JudgementLearning While Fidgeting: ADHDIt Is Not All PsychologicalParents of Children with ADHDChildren with ADHD and their FamiliesADHD Psychological Coaching: Learning to Cope without MedicationThe Amazing Story of a Boy Who Would Never Focus on AnythingI Thought I was Dumb: The Story of Ben Kilham, Bear ExpertAn Additional Comment About ADHD, It's Really RealADHD, It's Really RealInvolving Fathers in the Treatment of Children with ADHDAttention Deficit Disorder, A Personal AccountAdult ADHD: The Importance of Learning Social SkillsDo You Have Adult ADHD?Marriage, Family and Adult ADHDSmoking and ADHDDose-Response Curves and Treatment of ADHD, AddictionsNew drug warnings for ADHD stimulantsA New Way to Buffer Amphetamine For ADHD TreatmentTeachers as Brokers for ADHDPlaystation Neurofeedback Hybrid for ADHD TreatmentDaytrana skin patch for ADHD just approvedAdult ADHD: Difficult to Diagnose and Often Misunderstood VideosLinksBook ReviewsSelf-Help Groups |
| | | |
Intuniv Approved for Pediatric ADHD(HealthDay News) by -- Scott Roberts Updated: Sep 3rd 2009
THURSDAY, Sept. 3 (HealthDay News) -- Intuniv (guanfacine) has been approved by the U.S. Food and Drug Administration to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in people aged 6 to 17, drug maker Shire Plc said Thursday.
The once-daily drug, to be available in 1-to-4 mg. strengths, is expected on pharmacy shelves in November, the company said in a news release. The way it works is unclear, but the drug is thought to directly engage receptors in the brain's prefrontal cortex, an area that has been linked to the disorder.
Intuniv is not a controlled substance and "has no known potential for abuse or dependence," Shire said. It cited statistics from the U.S. Centers for Disease Control and Prevention (CDC) that some 4.4 million children in the United States have been diagnosed with ADHD.
In clinical testing, the most common adverse reactions to Intuniv included tiredness, abdominal pain, dizziness, a drop in blood pressure, dry mouth and constipation, the company said.
More information
The CDC has more about ADHD.
This article: Copyright © 2009 ScoutNews, LLC. All rights reserved. |
| 







|
|
|
|